Galectin Therapeutics (GALT) Competitors $1.29 -0.08 (-5.84%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. TRDA, BNTC, RNAC, MBX, SEPN, GLUE, PROK, ATAI, ATYR, and PHATShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Entrada Therapeutics (TRDA), Benitec Biopharma (BNTC), Cartesian Therapeutics (RNAC), MBX Biosciences (MBX), Septerna (SEPN), Monte Rosa Therapeutics (GLUE), ProKidney (PROK), Atai Life Sciences (ATAI), Atyr PHARMA (ATYR), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Entrada Therapeutics Benitec Biopharma Cartesian Therapeutics MBX Biosciences Septerna Monte Rosa Therapeutics ProKidney Atai Life Sciences Atyr PHARMA Phathom Pharmaceuticals Galectin Therapeutics (NASDAQ:GALT) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings. Do insiders and institutionals hold more shares of GALT or TRDA? 11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 50.1% of Galectin Therapeutics shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate GALT or TRDA? Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 749.42%. Entrada Therapeutics has a consensus target price of $25.67, suggesting a potential upside of 184.24%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media refer more to GALT or TRDA? In the previous week, Entrada Therapeutics had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 3 mentions for Entrada Therapeutics and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.89 beat Entrada Therapeutics' score of 0.53 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Galectin Therapeutics Very Positive Entrada Therapeutics Positive Which has higher valuation and earnings, GALT or TRDA? Entrada Therapeutics has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.76-1.70Entrada Therapeutics$210.78M1.63-$6.68M$1.914.73 Which has more volatility & risk, GALT or TRDA? Galectin Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Is GALT or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Galectin Therapeutics' net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Galectin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% Entrada Therapeutics 25.53%16.11%10.39% Does the MarketBeat Community prefer GALT or TRDA? Galectin Therapeutics received 326 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.00% of users gave Entrada Therapeutics an outperform vote while only 59.01% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34759.01% Underperform Votes24140.99% Entrada TherapeuticsOutperform Votes2184.00% Underperform Votes416.00% SummaryEntrada Therapeutics beats Galectin Therapeutics on 13 of the 18 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.82M$6.72B$5.49B$7.94BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-1.777.3722.5818.55Price / SalesN/A242.94397.25103.00Price / CashN/A65.8538.1834.62Price / Book-1.286.486.704.26Net Income-$41.07M$143.68M$3.23B$248.39M7 Day Performance-8.80%1.79%1.26%1.27%1 Month Performance2.78%6.68%3.75%3.85%1 Year Performance-63.00%-2.73%15.78%5.23% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.2894 of 5 stars$1.29-5.8%$11.00+752.7%-61.0%$81.82MN/A-1.779Positive NewsGap UpTRDAEntrada Therapeutics2.9936 of 5 stars$8.87+0.3%$25.67+189.4%-23.0%$333.47M$210.78M5.58110Upcoming EarningsNews CoverageBNTCBenitec Biopharma2.7034 of 5 stars$13.64+0.4%$24.71+81.2%+60.8%$319.87M$80,000.00-9.0320Positive NewsRNACCartesian Therapeutics1.9639 of 5 stars$12.21+3.2%$42.67+249.4%-45.6%$316.32M$38.91M-0.2364Upcoming EarningsMBXMBX Biosciences2.5943 of 5 stars$9.35+2.0%$37.50+301.1%N/A$312.51MN/A0.0036SEPNSepterna2.2586 of 5 stars$7.00+8.4%$33.00+371.4%N/A$311.09M$1.08M0.00N/ANews CoveragePositive NewsGLUEMonte Rosa Therapeutics1.9755 of 5 stars$4.95-2.2%$15.50+213.1%-7.7%$304.47M$75.62M-2.7090Upcoming EarningsShort Interest ↑News CoveragePROKProKidney2.4894 of 5 stars$1.03+1.0%$5.00+385.4%-57.1%$301.48M$76,000.00-1.873Positive NewsGap UpATAIAtai Life Sciences2.6871 of 5 stars$1.46flat$10.50+619.2%-24.2%$291.70M$308,000.00-1.8080Positive NewsATYRAtyr PHARMA2.3923 of 5 stars$3.27-2.4%$18.60+468.8%N/A$290.57M$235,000.00-3.4853Short Interest ↑News CoveragePHATPhathom Pharmaceuticals4.0483 of 5 stars$4.15+1.0%$21.83+426.1%-52.5%$288.99M$55.25M-0.73110News CoveragePositive NewsGap Down Related Companies and Tools Related Companies TRDA Alternatives BNTC Alternatives RNAC Alternatives MBX Alternatives SEPN Alternatives GLUE Alternatives PROK Alternatives ATAI Alternatives ATYR Alternatives PHAT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GALT Stock Free GALT Stock Alerts